Biogen Profit Beats Street Estimates as Cost-Cutting Takes Hold
(Bloomberg) -- Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug Leqembi gained traction and cost cuts took hold. Adjusted earnings for the quarter were $3.67 a share, the Cambridge, …